These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 33024022)
21. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials. Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K Mult Scler Relat Disord; 2016 Jul; 8():124-30. PubMed ID: 27456887 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Hernandez L; Guo S; Kinter E; Fay M J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984 [TBL] [Abstract][Full Text] [Related]
23. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250 [TBL] [Abstract][Full Text] [Related]
24. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. Dupuy SL; Khalid F; Healy BC; Bakshi S; Neema M; Tauhid S; Bakshi R BMC Med Imaging; 2016 Oct; 16(1):56. PubMed ID: 27716096 [TBL] [Abstract][Full Text] [Related]
25. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172 [TBL] [Abstract][Full Text] [Related]
26. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960 [TBL] [Abstract][Full Text] [Related]
27. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767 [TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA; Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650 [TBL] [Abstract][Full Text] [Related]
29. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
34. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Caon C; Din M; Ching W; Tselis A; Lisak R; Khan O Eur J Neurol; 2006 May; 13(5):471-4. PubMed ID: 16722971 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391 [TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Spelman T; Frisell T; Piehl F; Hillert J Mult Scler; 2018 Jul; 24(8):1087-1095. PubMed ID: 28649912 [TBL] [Abstract][Full Text] [Related]
37. Teriflunomide for multiple sclerosis. He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain. Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954 [TBL] [Abstract][Full Text] [Related]